Q-omics provides the consensus-scored GGCTP2 profile across patient tissues and cancer cell-line models. GGCTP2 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, GGCTP2 is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, GGCTP2 RNA expression shows 6,254 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, HNSC, and STAD as cancer lineages where GGCTP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GGCTP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GGCTP2 survival associations across molecular data types. GGCTP2 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GGCTP2 RNA expression–survival associations across cancer types. High GGCTP2 expression shows unfavorable associations in KICH, LIHC, READ, UVM, BRCA and UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for GGCTP2 RNA expression.
This table summarizes GGCTP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GGCTP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GGCTP2 shows higher tumor expression in HNSC and LUAD. The HNSC box plot shows higher GGCTP2 RNA expression in tumor versus normal tissue (log2 FC = +0.108, t-test p = .026).
This table shows molecular features associated with GGCTP2 in patient tissues and cancer cell lines. In patient samples, GGCTP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
